# EDGAR Filing Document

**Accession Number:** 0001087294
**File Stem:** 0001087294-25-000008
**Filing Date:** 2025-10
**Character Count:** 7474
**Document Hash:** 58dd0134d1098eea526fe58988501b0c
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001087294-25-000008.hdr.sgml**: 20251003

**ACCESSION NUMBER**: 0001087294-25-000008

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20250902

**FILED AS OF DATE**: 20251003

**DATE AS OF CHANGE**: 20251003

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Jones James
- **CENTRAL INDEX KEY:** 0001490829

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-33637
- **FILM NUMBER:** 251373661

**MAIL ADDRESS:**
- **STREET 1:** 1600 WEST END AVE., SUITE 1300
- **STREET 2:** SUITE 1300
- **CITY:** NASHVILLE
- **STATE:** TN
- **ZIP:** 37203
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** CUMBERLAND PHARMACEUTICALS INC
- **CENTRAL INDEX KEY:** 0001087294
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 621765329
- **STATE OF INCORPORATION:** TN
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 1600 WEST END AVENUE
- **STREET 2:** SUITE 1300
- **CITY:** NASHVILLE,
- **STATE:** TN
- **ZIP:** 37203
- **BUSINESS PHONE:** 615-255-0068

**MAIL ADDRESS:**
- **STREET 1:** 1600 WEST END AVENUE
- **STREET 2:** SUITE 1300
- **CITY:** NASHVILLE
- **STATE:** TN
- **ZIP:** 37203

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[x] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Jones James<br><sub>(Last) (First) (Middle)</sub><br>1600 WEST END AVENUE, SUITE 1300<br><sub>(Street)</sub><br>NASHVILLE, TN 37203<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2025-09-02 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director [ ] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>CUMBERLAND PHARMACEUTICALS INC [ CPIX ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Stock | 2025-09-02 |  | L | V | 12<sup>(1)</sup> | A | $3.54 | 43950 | D |  |
| Common Stock | 2025-09-03 |  | L | V | 12<sup>(1)</sup> | A | $3.58 | 43962 | D |  |
| Common Stock | 2025-09-04 |  | L | V | 12<sup>(1)</sup> | A | $3.60 | 43974 | D |  |
| Common Stock | 2025-09-05 |  | L | V | 12<sup>(1)</sup> | A | $3.60 | 43986 | D |  |
| Common Stock | 2025-09-08 |  | L | V | 12<sup>(1)</sup> | A | $3.41 | 43998 | D |  |
| Common Stock | 2025-09-09 |  | L | V | 12<sup>(1)</sup> | A | $3.43 | 44010 | D |  |
| Common Stock | 2025-09-10 |  | L | V | 12<sup>(1)</sup> | A | $3.39 | 44022 | D |  |
| Common Stock | 2025-09-11 |  | L | V | 12<sup>(1)</sup> | A | $3.41 | 44034 | D |  |
| Common Stock | 2025-09-12 |  | L | V | 12<sup>(1)</sup> | A | $3.54 | 44046 | D |  |
| Common Stock | 2025-09-15 |  | L | V | 12<sup>(1)</sup> | A | $3.50 | 44058 | D |  |
| Common Stock | 2025-09-16 |  | L | V | 12<sup>(1)</sup> | A | $3.50 | 44070 | D |  |
| Common Stock | 2025-09-17 |  | L | V | 12<sup>(1)</sup> | A | $3.38 | 44082 | D |  |
| Common Stock | 2025-09-18 |  | L | V | 12<sup>(1)</sup> | A | $3.31 | 44094 | D |  |
| Common Stock | 2025-09-19 |  | L | V | 12<sup>(1)</sup> | A | $3.34 | 44106 | D |  |
| Common Stock | 2025-09-22 |  | L | V | 12<sup>(1)</sup> | A | $3.29 | 44118 | D |  |
| Common Stock | 2025-09-23 |  | L | V | 12<sup>(1)</sup> | A | $3.21 | 44130 | D |  |
| Common Stock | 2025-09-24 |  | L | V | 12<sup>(1)</sup> | A | $3.10 | 44142 | D |  |
| Common Stock | 2025-09-25 |  | L | V | 12<sup>(1)</sup> | A | $3.10 | 44154 | D |  |
| Common Stock | 2025-09-26 |  | L | V | 12<sup>(1)</sup> | A | $3.05 | 44166 | D |  |
| Common Stock | 2025-09-29 |  | L | V | 13<sup>(1)</sup> | A | $3.14 | 44179 | D |  |
| Common Stock | 2025-09-30 |  | L | V | 13<sup>(1)</sup> | A | $3.12 | 44192 | D |  |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |

---

### Footnotes:

(1) The reported purchase occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2024.

**Signature:** James Jones by /s/ John Hamm as attorney-in-fact  
**Date:** 2025-10-03

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**